# Melanotans

Sonoran UV Biology · Clinical & Regulatory Field Report

**Directory:** [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Scenesse](/afamelanotide-scenesse) · [Vyleesi](/bremelanotide-vyleesi) · [Imcivree](/setmelanotide-imcivree) · [Online Market](/melanotan-online-market) · [Case Reports](/case-reports-and-safety) · [Regulators](/regulatory-warnings) · [References](/references) · [About](/about)

**Prescription Medicine · Cyclic 8-Amino-Acid Disulfide Peptide · MC4R Agonist** · Dispatch 05 · Setmelanotide (Imcivree)

---

[Melanotans](/) / Setmelanotide (Imcivree)

# Setmelanotide (Imcivree): Engineering around the blood-pressure wall in rare MC4R obesity

Of all five melanocortin switches, MC4R carried major metabolic promise—and a sharp cardiovascular hurdle. Setmelanotide cleared trials for specific genetic and acquired hypothalamic obesity disorders, yet retains a melanocortin footprint on skin, mood, and sexual arousal.

**Field Record 07 · Appetite Circuit:** Brain `MC4R` signaling regulates [food intake and energy balance in mouse knockout studies](https://pubmed.ncbi.nlm.nih.gov/9019399/); FDA's [March 2026 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) explicitly excludes general (polygenic) obesity.

## The cardiovascular hurdle and 20-fold MC4R selectivity

In 1997, targeted gene inactivation in mice showed that [disrupting `MC4R` causes maturity-onset obesity with hyperphagia, hyperinsulinemia, and hyperglycemia](https://pubmed.ncbi.nlm.nih.gov/9019399/); a year later, [Krude et al. (1998) documented human *POMC* mutations](https://pubmed.ncbi.nlm.nih.gov/9620771/) pairing early-onset obesity with adrenal insufficiency and red hair. Early clinical MC4R obesity candidates—`MK-0493`, `LY2112688`, `MC4-NN-0453`, and `AZD2820`—failed in human trials despite preclinical efficacy, with purported MC4R-selective compounds identifying [hypertension, increased heart rate, skin darkening, and sexual arousal](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/).

**Setmelanotide (Imcivree)** is an [8-amino-acid cyclic disulfide peptide analog of α-MSH](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) (`C49H68N18O9S2`, free-base mass **1117.3 Daltons**; median `tmax` **8 hours**, effective elimination half-life **~11 hours**, no clinically relevant QT prolongation). FDA's March 2026 label describes it as an MC4R agonist with **20-fold less activity at MC3R and MC1R**; in human-receptor assays compiled by [Yuan & Tao (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/) (Kievit et al., 2013), `EC50` is **0.27 nM** at MC4R versus **5.3 nM** (MC3R), **5.8 nM** (MC1R), and **1600 nM** (MC5R). Preclinical work summarized by Yuan & Tao indicates setmelanotide [potently activates MC4R `Gαq` signaling resistant to AgRP antagonism](https://pmc.ncbi.nlm.nih.gov/articles/PMC9599618/), reducing food intake without cardiovascular pressor effects.

## Dated U.S. FDA and EU EMA indications and eligibility boundaries

**United States ([FDA Prescribing Information; Initial U.S. Approval: 2020; Revised: 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)):** "IMCIVREE is a melanocortin 4 (MC4) receptor agonist indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged (1): 4 years and older with acquired hypothalamic obesity (HO). 2 years and older with Bardet-Biedl syndrome (BBS). 2 years and older with pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS)." The label notes: "An FDA-approved test for the detection of variants in the POMC, PCSK1, or LEPR genes is not available." Under Limitations of Use: "IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign. Other types of obesity not related to acquired HO, BBS, or POMC, PCSK1 or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity."

**European Union ([EMA EPAR; Last updated: 27/05/2026](https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree); latest procedure affecting product information dated 30/04/2026):** "Imcivree received a marketing authorisation valid throughout the EU on 16 July 2021." The EPAR update states Imcivree is used "in adults and children aged 4 years and older with acquired hypothalamic obesity (aHO), a condition that occurs when the hypothalamus (a part of the brain) does not work properly, either following an injury or because of an underlying disease;" "in adults and children aged 2 years and older who have pro-opiomelanocortin (POMC) deficiency, proprotein convertase subtilisin/kexin type 1 (PCSK1) deficiency, or leptin receptor (LEPR) deficiency; these genetic conditions result from changes (mutations) in both copies of the genes responsible for making POMC, PCSK1 or LEPR;" and "in adults and children aged 2 years and older with a genetic condition called Bardet Biedl syndrome (BBS)."

**Figure 6 · Pivotal 52-Week Clinical Outcomes.** Open-label genetic trials tracked weight (Trials 3–4) or BMI (Trial 2); TRANSCEND tracked placebo-controlled BMI in acquired HO. Sources: [FDA Label (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf); [Miller et al. (NEJM, July 9, 2026)](https://pubmed.ncbi.nlm.nih.gov/42418774/).

## Pivotal Rhythm Pharmaceuticals–funded trials

Trials 3 and 4 (ages ≥6) enrolled patients with homozygous or presumed compound heterozygous variants and excluded double heterozygotes in two different genes ([FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)); [Clément et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/33137293/) reported most-hunger changes of **−27.1%** (*n* = 7, *p* = 0.0005) in POMC and **−43.7%** (*n* = 7, *p* < 0.0001) in LEPR, while 4-week blinded placebo withdrawal in 16 responders produced **5.5 kg** and **5.0 kg** average regain ([FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)). In Trial 2 (ages ≥6), [Haqq et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36356613/) saw **32.3%** of BBS patients ≥12 reach ≥10% weight loss at 52 weeks (*p* = 0.0006; Alström inconclusive), and FDA's label reports 14-week placebo-adjusted BMI change of **−4.5%** (*N* = 44 BBS). Open-label Trial 5 (NCT04966741; ages 2 to <6; *N* = 12: 3 POMC, 4 LEPR, 5 BBS, none PCSK1) showed 52-week BMI changes of **−33.8%**, **−13.1%**, and **−9.7%** (8% discontinuation; [FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)). In acquired HO (TRANSCEND / Trial 1), [Miller et al. (July 9, 2026)](https://pubmed.ncbi.nlm.nih.gov/42418774/) reported a 52-week LSM BMI change of **−16.5% vs. +3.3%** (*P* < 0.001) and, in participants aged 12 or older, a change in the weekly average of maximal daily hunger of **−2.73 vs. −1.45** (*P* = 0.009), while [FDA's label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) reported **60.99% vs. 4.69%** reaching ≥10% BMI loss (10.6% vs. 12.5% discontinuation).

### Setmelanotide Pivotal Cohorts Across Indications

| Indication & Trial | Design & Cohort | 52-Week Primary / Key Outcome | Primary Source |
|---|---|---|---|
| POMC / PCSK1 (Trial 3, NCT02896192) | Open-label + 8-wk withdrawal (*n* = 10, ages ≥6) | 80% ≥10% wt; mean −23.1% wt (*P* = 0.0003) | [FDA (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf); [Clément (2020)](https://pubmed.ncbi.nlm.nih.gov/33137293/) |
| LEPR (Trial 4, NCT03287960) | Open-label + 8-wk withdrawal (*n* = 11, ages ≥6) | 46% (45% Clément) ≥10% wt; mean −9.7% wt (*P* = 0.0074) | [FDA (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf); [Clément (2020)](https://pubmed.ncbi.nlm.nih.gov/33137293/) |
| Bardet-Biedl (Trial 2, NCT03746522) | 14-wk RCT + 52-wk open-label (*N* = 31 BBS, ages ≥6) | Mean −7.9% BMI; 38.7% ≥10% BMI (Alström inconclusive) | [FDA (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf); [Haqq (2022)](https://pubmed.ncbi.nlm.nih.gov/36356613/) |
| Acquired HO (Trial 1 / TRANSCEND, NCT05774756) | Double-blind RCT with a 52-week treatment period after titration (*n* = 120 NEJM / *N* = 142 FDA, ages ≥4) | −16.5% vs. +3.3% BMI (NEJM, *P* < 0.001); −18.40% diff (FDA) | [Miller (2026)](https://pubmed.ncbi.nlm.nih.gov/42418774/); [FDA (03/2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) |

[The March 2026 FDA label says its trials included no patients aged 65 or older](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf). [The published TRANSCEND trial included participants aged 4 to 66](https://pubmed.ncbi.nlm.nih.gov/42418774/). FDA's label also notes no pregnancy data, recommends against breastfeeding, does not recommend use in end-stage renal disease (`eGFR` <15 mL/min/1.73 m²), and notes short-term testing in 12 otherwise healthy patients with obesity is not an approved use.

## Cross-receptor footprint, mood, and 2026 endocrine warnings

- **MC1R pigment and moles:** Skin hyperpigmentation occurred in **58% vs. 10%** placebo in acquired HO (*N* = 142), **63%** in BBS (*N* = 43), **78%** in POMC/PCSK1/LEPR (*N* = 27), and **83%** in ages 2 to <6 (*N* = 12; [FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)), with pooled rates on FDA's [December 2024 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf) reported as **67%** (ages ≥6) and **83%** (ages 2 to <6). Melanocytic nevi occurred in **14% to 19%** across older cohorts and **33%** in Trial 5 ([FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)); FDA directs full-body skin exams before and during therapy. A 2025 review (Rhythm Pharmaceuticals editorial support) reported [two fair-skinned Fitzpatrick II BBS patients with heavy UV exposure diagnosed with stage pT1a melanoma](https://pmc.ncbi.nlm.nih.gov/articles/PMC11664455/), both excised.
- **Erections, mood, and hypersensitivity:** Spontaneous penile erections occurred in **23%** (*n* = 13 males, Trials 3–4), **25%** (*n* = 20 males, BBS), and **8%** (Trial 5; [FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf))—and, in acquired HO, spontaneous erections or increased erection frequency were reported in **7% of the treated group and 4% of the placebo group** ([FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)); pooled [December 2024 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/213793s007lbl.pdf) figures include **24%** in males ≥6 and **7%** sexual adverse reactions in females ≥6. Trials 3–4 recorded **depression (26%)** and **suicidal ideation (11%)**, and Trial 5 recorded depressed mood (8%; [FDA Label 03/2026](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf)). Imcivree is contraindicated after prior serious hypersensitivity, including postmarketing anaphylaxis.
- **2026 acquired HO warnings:** In TRANSCEND, adverse events occurred in **100% vs. 90%** and serious adverse events in **28% vs. 8%** ([Miller et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42418774/)). FDA's [March 2026 label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/213793s009lbl.pdf) added warnings for **acute adrenal insufficiency** (serious reactions in **5% vs. 0%** placebo among patients with secondary adrenal insufficiency) and **sodium imbalance** (**6% vs. 2%** hyponatremia; **5% vs. 4%** hypernatremia in central diabetes insipidus). Across five ≥52-week trials, **4/245 (1.6%)** developed anti-setmelanotide and **17/245 (6.9%)** anti-α-MSH antibodies (generally low titers; clinical impact undetermined); 26-week Tg.rasH2 mice showed no carcinogenicity.

---

## Prescription Dossier · Imcivree

- **Generic / Brand:** Setmelanotide (Imcivree)
- **Dated Agency Records:** FDA label (Initial Approval 2020; Revised 03/2026); EMA EPAR (EU authorization July 16, 2021; EPAR updated May 27, 2026)
- **Chemical & PK Profile:** Cyclic 8-aa disulfide peptide (`MW 1117.3 Da`); 20× less active at MC3R & MC1R; `t½` ~11 h
- **Rhythm-Funded Trials:** `NCT02896192`, `NCT03287960`, `NCT03746522`, `NCT04966741`, TRANSCEND `NCT05774756`

### Compare Other Dispatches
- [03. Afamelanotide (Scenesse)](/afamelanotide-scenesse)
- [04. Bremelanotide (Vyleesi)](/bremelanotide-vyleesi)
- [06. Online Melanotan I & II: Lab Assays](/melanotan-online-market)
- [02. Five Receptors Biology](/five-receptors)

- Previous Dispatch · 04: [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi)
- Next Dispatch · 06: [Online Melanotan I & II: Lab Assays](/melanotan-online-market)

---

**Melanotans** is an independent educational pharmacology field report on melanocortin receptor biology, prescription medicines afamelanotide (Scenesse), bremelanotide (Vyleesi), and setmelanotide (Imcivree), and online products sold as Melanotan I and II—not a laboratory, manufacturer, clinic, pharmacy, telehealth service, or seller, and never medical advice.

- Plain-text edition: [setmelanotide-imcivree.md](/setmelanotide-imcivree.md) · Full bibliography: [Primary Source Ledger](/references)
- Pathway & Prescription Medicines: [Tucson Origin](/tucson-origin) · [Five Receptors](/five-receptors) · [Afamelanotide (Scenesse)](/afamelanotide-scenesse) · [Bremelanotide (Vyleesi)](/bremelanotide-vyleesi) · [Setmelanotide (Imcivree)](/setmelanotide-imcivree)
- Online Market, Safety & Charter: [Online Market & Lab Assays](/melanotan-online-market) · [Case Reports & Safety](/case-reports-and-safety) · [Regulatory Warnings](/regulatory-warnings) · [References](/references) · [About](/about) · [Contact](/contact)
